WuXi PharmaTech CEO Appointed to CrossFire Beilstein Database Advisory Board

WuXi PharmaTech CEO Appointed to CrossFire Beilstein Database Advisory Board

August 24, 2007

    SHANGHAI, China, Aug. 24 /Xinhua-PRNewswire/ -- WuXi
PharmaTech (NYSE: WX), China's premier provider of
pharmaceutical R&D outsourcing services announced today
Dr. Ge Li, the Company's Chairman and Chief Executive
Officer, is appointed to a newly established advisory board
of Elsevier Information Systems GmbH.

    (Logo: http://www.xprn.com/xprn/sa/200611271812-min.jpg
)

    Elsevier Information Systems GmbH, a subsidiary of
Elsevier, the leading global publisher of scientific,
technical and medical information, recently established an
Advisory Board in order to further improve the CrossFire
Beilstein Database, the world's largest organic chemistry
and chemical facts database.  The Advisory Board consists
of eleven industry experts including two Nobel
laureates¡ªProf. Robert H. Grubbs from California Institute
of Technology and Dr. K. Barry Sharpless from Scripps
Research Institute.

    In early 2006 WuXi PharmaTech became the largest
CrossFire Beilstein user in China by number of user seats. 
Now the Company is the largest user of the database in the
world by search volume.

    "It is a great honor to be a member of such a
notable selection of industry leaders.  I am very pleased
to serve in an advisory role for such a high quality drug
discovery and research tool," commented Dr. Ge Li,
Chairman and Chief Executive Officer of WuXi PharmaTech. 
"The database is such an indispensable resource that
our scientists rely on it to support the drug discovery
efforts of our global pharmaceutical and biotechnology
clients."

    About WuXi PharmaTech Co., Ltd.

    Founded in 2000, Shanghai-based WuXi PharmaTech is the
leading China-based pharmaceutical and biotechnology
R&D outsourcing company.  As a research- driven and
customer-focused company, WuXi PharmaTech provides
pharmaceutical and biotechnology companies a broad and
integrated portfolio of laboratory and research
manufacturing services throughout the drug discovery and
development process.  WuXi PharmaTech's services are
designed to assist its global partners in shortening the
cycle and lowering the cost of drug discovery and
development by providing cost-effective and efficient
outsourcing solutions that save its customers both time and
money.  Its operations are grouped into two segments:
laboratory services, consisting of discovery chemistry,
service biology, analytical, pharmaceutical development and
process development services, and manufacturing, focusing on
manufacturing of advanced intermediates and active
pharmaceutical ingredients for R&D use.  In 2006, WuXi
PharmaTech provided services to 70 pharmaceutical and
biotechnology customers, including nine of the top ten
pharmaceutical companies in the world, as measured by 2006
total revenues.  For more information, please visit:
http://www.wuxipharmatech.com .



    For more information, please contact:
   
     Sherry Shao
     Tel:   [phone]
     Email: [e-mail]